{
    "nctId": "NCT05331807",
    "briefTitle": "Omega-3 and Vitamin D Supplementation in Breast Cancer Women",
    "officialTitle": "The Effects of Combined Omega-3 and Vitamin D Supplementation on Nutritional Status, Quality of Life and Inflammatory Markers Among the Breast Cancer Women in Gaza Strip",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer Female",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 88,
    "primaryOutcomeMeasure": "Change of Nutritional status, as assessed by Body Mass Index",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Females who have been newly diagnosed with the breast cancer of stage I, II and III\n* Patients with following clinical diagnosis of breast cancer such as lymph node positive +ve, hormonal receptor negative -ve and human epidermal growth factor receptor 2 (HER2) negative -ve\n* Patient will receive her first chemotherapy treatment with Adriamycin + Cytoxan (AC) for a total of four cycle (each cycle will be carried-out every 3 weeks (21 days)\n\nExclusion Criteria:\n\n* Participants who had already undertaken her chemotherapy previously, and/or other oncology treatments such as hormonal or radiation oncology therapy\n* Patients with recurrent breast cancer, patients with other chronic disease conditions such as renal disease and under dialysis, HIV, malabsorption disorder diseases, autoimmune diseases, diabetes, hypertension, hepatic, parathyroid, and gastrointestinal disorders.\n* Patients who have reported any allergy condition to fish and/or fish products\n* Pregnant women",
    "sex": "FEMALE",
    "minimumAge": "19 Years",
    "stdAges": "ADULT"
}